Susquehanna International Group
MLNT

Susquehanna International Group’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Susquehanna International Group’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-143,285
Closed -$516K – 11190
2019
Q2 		$953K Buy
+143,285
New +$545K ﹤0.01% 5778
2019
Q1 		– Sell
-5,120
Closed -$27.8K – 10363
2018
Q4 		$20K Buy
5,120
+1,181
+30% +$15.1K ﹤0.01% 8683
2018
Q3 		$78K Buy
+3,939
New +$99.6K ﹤0.01% 8697
2018
Q2 		– Sell
-4,057
Closed -$146K – 10817
2018
Q1 		$150K Sell
4,057
-2,727
-40% -$179K ﹤0.01% 8527
2017
Q4 		$536K Buy
+6,784
New +$502K ﹤0.01% 6508

Susquehanna International Group's MLNT Position: Q3 2019 in Review

Susquehanna International Group sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q3 2019, closing a stake of 143,285 shares — an estimated $516K sold.

Susquehanna International Group first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $953K in Q2 2019. 47 funds tracked by Wall St. Rank hold MLNT as of Q3 2019.

  • Susquehanna International Group reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Susquehanna International Group sold 143,285 Melinta Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $516K.
  • Susquehanna International Group first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
  • Susquehanna International Group's Melinta Therapeutics, Inc. Common Stock position peaked at $953K in Q2 2019.
  • 47 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Susquehanna International Group's 13F filing for Q3 2019, filed 14 Nov 2019.